Naltrexone vs Phenibut
FDA Approved vs Moderate Research
monitor Researched · 90% Both compounds affect neurological signaling pathways. Phenibut acts on GABA-B receptors while naltrexone modulates the opioid system. While there is no direct pharmacological antagonism, both substances influence mood and reward circuitry. Monitor for unexpected changes in mood, sedation, or tolerance patterns when used concurrently.
Molecular Data
Naltrexone Phenibut
Weight 341.40 Da 179.22 Da
Half-life ~4 hours ~5 hours
Type Opioid antagonist (C20H23NO4) Phenyl-substituted GABA analog (C10H13NO2)
Key Benefits
Naltrexone
01 Broad anti-inflammatory and immunomodulatory effects via OGF-OGFr axis upregulation
02 Reduction in pro-inflammatory cytokines (TNF-alpha, IL-6, IL-12) through TLR4 antagonism
03 Compensatory upregulation of endogenous endorphins and enkephalins (200-300% increase)
04 Improved immune regulation and rebalancing of Th1/Th2/Th17 responses
05 Reduction in chronic pain through central and peripheral opioid system modulation
06 Potential improvement in mood, anhedonia, and overall well-being via endorphin enhancement
07 Extremely well-tolerated with minimal side effects at low doses
08 Low cost, especially as compounded LDN formulation
Phenibut
01 Reduction of anxiety and social inhibition
02 Improved sleep onset and sleep quality
03 Mild mood elevation and sense of well-being
04 Reduced cognitive effects of stress without heavy sedation at low doses
05 Potential benefit for vestibular disorders (clinical use in Russia)
Side Effects
Naltrexone
Vivid dreams or unusually intense dreaming - the most frequently reported side effect, typically diminishes over 1-2 weeks
Initial sleep disruption or insomnia during the first week of treatment
Mild nausea, particularly during the first few days
Transient headache during dose initiation or titration
Phenibut
Drowsiness and sedation, especially at higher doses
Dizziness and lightheadedness
Nausea and gastrointestinal discomfort (particularly with HCl form on empty stomach)
Tolerance develops rapidly, often within 2-3 days of consecutive use
Next-day grogginess or hangover-like effects
Headache
Contraindications
Current use of opioid medications or active opioid dependence (must be opioid-free 7-10 days minimum)
Acute hepatitis or severe hepatic impairment (primarily relevant at full dose)
Known hypersensitivity to naltrexone
Anticipated need for opioid pain medication (e.g., upcoming surgery - discontinue LDN 3-7 days prior)
History of substance abuse or addiction (phenibut has high abuse potential)
Concurrent use of alcohol, benzodiazepines, GHB, barbiturates, or other CNS depressants
Renal impairment (phenibut is primarily excreted by the kidneys)
Pregnancy and breastfeeding (insufficient safety data)
History of seizure disorders (withdrawal may lower seizure threshold)
Current dependence on any GABAergic substance
Research Evidence
Naltrexone Phenibut
Status FDA Approved Moderate Research
References 5 studies 5 studies
Latest 2023 2020
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.